+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN8601) in patients with advanced malignancy



Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN8601) in patients with advanced malignancy



Cancer Research 49(18): 5221-5224



To evaluate the toxicity and efficacy of recombinant human granulocyte-colony-stimulating factor (rh G-CSF) administered with intensive chemotherapy, 39 patients with advanced pulmonary cancers were enrolled in a dose escalation trial of rh G-CSF. Three days after initiation of chemotherapy rh G-CSF was administered i.v. for 14 consecutive days at five dose levels (50-800 micrograms/m2). Absolute neutrophil counts showed a dose-dependent increase with an increasing dose of rh G-CSF and the durations of neutropenia (less than 1000/mm3) shortened significantly at doses of 200, 400, and 800 micrograms/m2 compared to those at 50 micrograms/m2 (P less than 0.01). The duration of neutropenia was shortened significantly at all five dose levels following treatment with rh G-CSF compared to treatment without rh G-CSF (P less than 0.05). Adverse side effects associated with rh G-CSF administration were fever higher than 38 degrees C (21%), chest pain, and low back pain (13%). No intolerable side effects were experienced. It can be concluded that rh G-CSF is effective in shortening the duration of neutropenia following intensive chemotherapy at a dose level of 100 to 200 micrograms/m2 i.v. a 400-micrograms/m2 dose of rh G-CSF is recommended in patients with prior treatment because of the possibility of a lower bone marrow response.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 039865649

Download citation: RISBibTeXText

PMID: 2475245


Related references

Subcutaneous administration of recombinant human granulocyte colony-stimulating factor (KRN8601) in intensive chemotherapy for patients with advanced lung cancer. Japanese Journal of Cancer Research 81(11): 1168-1174, 1990

A study of dose escalation of teniposide (VM-26) plus cisplatin (CDDP) with recombinant human granulocyte colony-stimulating factor (rhG-CSF) in patients with advanced small cell lung cancer. European Journal of Cancer 30A(2): 188-194, 1994

Phase i ii study of recombinant human granulocyte macrophage colony stimulating factor in patients with advanced malignancy. Acta Haematologica 87(1-2): 22-28, 1992

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy: a phase Ib trial. Journal of the National Cancer Institute 82(8): 697-703, 1990

Phase l/ll Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Advanced Malignancy. Acta Haematologica 87(1-2): 22-28, 1992

Phase I study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. Bulletin du Cancer (Paris) 80(5): 418-430, 1993

Effects of bacterially synthesized recombinant human granulocyte macrophage colony stimulating factor in patients with advanced malignancy. Annals of Internal Medicine 110(5): 357-364, 1989

Hematopoietic responses in patients with advanced malignancy treated with recombinant human granulocyte-macrophage colony-stimulating factor. Journal of Clinical Oncology 7(2): 159-167, 1989

Influence of renal and hepatic failure on the pharmacokinetics of recombinant human granulocyte colony-stimulating factor (KRN8601) in the rat. Cancer Research 50(20): 6615-6619, 1990

Dose-escalation study of biweekly CHOP using recombinant human granulocyte-colony stimulating-factor in non-Hodgkins lymphoma. Blood 82(10 Suppl. 1): 144A, 1993

Dose intensification by using human recombinant granulocyte-macrophage colony stimulating factor in advanced breast cancer patients. European Journal of Gynaecological Oncology 17(5): 411-413, 1996

Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in patients with advanced malignancy. The Multicenter Study Group. Acta Haematologica 87(1-2): 22-28, 1992

Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Cancer 74(7): 1939-1944, 1994

Double-blind, randomized comparison of the safety profile of granulocyte macrophage colony stimulating factor vs recombinant granulocyte colony stimulating factor in advanced HIV infected patients with neutropenia. Program & Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 33: 246, 1993

Dose Escalation of Radioantibody in a Mouse Model With the Use of Recombinant Human Interleukin-1 and Granulocyte-Macrophage Colony-Stimulating Factor Intervention to Reduce Myelosuppression. Jnci Journal of the National Cancer Institute 84(6): 399-407, 1992